How Compounding Pharmacies Make Peptides

Compounding Pharmacy Quality

USP 797 standard

Revised USP 797, effective November 2023, raised sterile compounding requirements for environmental monitoring, personnel garbing, and beyond-use dating.

United States Pharmacopeia, 2023

United States Pharmacopeia, 2023

View as image

Injectable peptides from compounding pharmacies arrive in small vials that look identical to pharmaceutical products. The process behind those vials, however, is fundamentally different from drug manufacturing. Compounding pharmacies operate under different laws, different oversight structures, and different quality standards than pharmaceutical companies. Understanding those differences matters because the peptide inside the vial is only as reliable as the process that put it there.

PCAB accreditation provides one quality benchmark, but accreditation is voluntary. The mandatory baseline comes from United States Pharmacopeia (USP) chapters, state pharmacy boards, and federal frameworks that govern what compounders can make and how they must make it.

What compounding pharmacies actually do

A compounding pharmacy does not synthesize peptides. Solid-phase peptide synthesis (SPPS), the standard method for creating peptide chains from individual amino acids, requires specialized equipment, chemistry expertise, and quality controls that exist at dedicated manufacturing facilities, not retail or outsourcing pharmacies.

What compounding pharmacies do is obtain bulk active pharmaceutical ingredients (APIs) from registered suppliers and formulate them into patient-ready dosage forms. For injectable peptides, this means:

1. Sourcing API. The pharmacy purchases lyophilized (freeze-dried) peptide powder from an FDA-registered supplier. The API comes with a Certificate of Analysis (CoA) documenting identity, purity, potency, and microbial limits. The quality of the final product depends heavily on API quality. Reputable pharmacies verify CoAs through independent testing rather than relying solely on supplier documentation.

2. Reconstitution and formulation. The lyophilized peptide is reconstituted in bacteriostatic water or sterile saline under aseptic conditions. The pharmacy may adjust concentration, add excipients (like mannitol for lyoprotection or methionine for oxidation prevention), or combine peptides per physician orders. This step introduces variables: water quality, mixing technique, filter compatibility, and excipient selection all affect the final product. Peptides are sensitive to shear stress during mixing and can aggregate or degrade if handled improperly.

3. Sterile filling. The formulated solution is filtered through 0.22-micron filters (which remove bacteria but not endotoxins, viruses, or dissolved contaminants) and filled into sterile vials in a controlled clean room environment under ISO Class 5 or better conditions. The fill process must maintain aseptic technique throughout. Each vial closure must be properly sealed and inspected.

4. Testing. Finished products undergo quality testing before release. The scope and depth of testing varies between pharmacies (see quality testing section below).

5. Labeling and dispensing. Each vial is labeled with peptide identity, concentration, lot number, beyond-use date, and storage conditions. Compounded products are dispensed against individual patient prescriptions (503A) or in anticipation of orders without prescriptions (503B).

The legal distinction between 503A and 503B pharmacies determines the scope of testing, batch sizes, and oversight requirements.

USP 797: the sterile compounding standard

USP General Chapter 797 is the foundational standard for sterile compounding in the United States. The revised chapter, effective November 1, 2023, raised requirements in several areas directly relevant to peptide compounding.

Environmental monitoring

Clean rooms must be continuously monitored for viable and non-viable particle counts. Air sampling, surface sampling, and personnel sampling must meet defined limits. ISO Class 5 conditions (fewer than 3,520 particles per cubic meter at 0.5 micron or larger) are required in the primary engineering control (laminar airflow workbench or isolator).

Personnel competency

Staff performing sterile compounding must pass initial and ongoing competency assessments including aseptic technique validation (media fill testing), garbing proficiency, and hand hygiene verification. Media fills use growth media instead of actual drug; if bacteria grow, the operator's technique is inadequate.

Beyond-use dating

Beyond-use dates (BUDs) define how long a compounded preparation can be stored before use. Under revised USP 797, BUDs must be supported by either stability-indicating testing specific to the preparation or default conservative timeframes. Default BUDs for sterile preparations compounded from non-sterile starting ingredients are as short as 24 hours at room temperature without sterility testing.

This is a known weak point. Many compounders have historically assigned BUDs based on informal vendor guidance or convention rather than product-specific stability data. Peptides are particularly sensitive to degradation through oxidation, deamidation, and aggregation, making BUD assignment a meaningful quality variable.

Immediate-use preparations

USP 797 allows a narrow category of "immediate-use" preparations with simplified requirements, but these must be used within specific timeframes and cannot be stored. Most compounded peptide products do not qualify for this exemption.

Quality testing requirements

Compliant compounding pharmacies test finished preparations for multiple quality attributes:

Sterility testing. Confirms absence of viable microorganisms. Performed using membrane filtration or direct inoculation methods per USP 71. Results take 14 days, meaning product may be released before sterility results are final under some conditions.

Bacterial endotoxin testing (BET). Detects pyrogenic substances from gram-negative bacteria. Performed using the Limulus amebocyte lysate (LAL) assay per USP 85. Endotoxin contamination can cause fever, inflammation, and sepsis even in a "sterile" product.

Potency testing. Verifies the peptide concentration matches the label claim. Typically performed using high-performance liquid chromatography (HPLC) or UV spectrophotometry. Potency must fall within defined limits (usually 90-110% of label claim for compounded sterile preparations).

Identity testing. Confirms the peptide in the vial is the correct molecule. May use HPLC retention time comparison, mass spectrometry, or other analytical methods.

Purity testing. Measures degradation products, related substances, and impurities. This is where compounded and pharmaceutical-grade peptides can differ most.

Why manufacturing process matters for peptide quality

Hach and colleagues (2024) studied how manufacturing process and compounding conditions affect the quality of follow-on GLP-1 polypeptide drugs. They found measurable differences in impurity profiles, aggregation, and degradation products between preparations made under different conditions. Even when starting from the same API, differences in reconstitution technique, filtration, storage temperature, and formulation excipients produced preparations with distinct quality profiles.^[1]

These differences are not academic. Verbeken and colleagues (2012) demonstrated that peptide impurity profiles directly affect biological function. Using tissue organ bath assays with the 11-mer peptide INSL6[151-161], they showed that preparations with different impurity profiles produced different functional responses, even when the primary peptide content was identical. Trace impurities acted as agonists, antagonists, or modulators of the intended peptide's activity.^[2]

This means a compounded peptide that passes potency testing (correct amount of primary peptide) may still behave differently from a pharmaceutical-grade product if its impurity profile differs. Potency testing alone does not guarantee functional equivalence. This gap between analytical purity and biological equivalence is one of the least discussed but most consequential issues in peptide compounding quality.

The safety data gap

McCall and colleagues (2026) conducted a safety analysis of compounded pharmaceutical products, examining adverse event reports and quality deviations across compounded preparations. Their analysis highlighted that while serious adverse events from compounded sterile preparations are relatively rare, underreporting is likely given that compounded products lack the structured pharmacovigilance systems required of FDA-approved drugs.^[3]

The 2012 New England Compounding Center (NECC) meningitis outbreak, which killed 76 people from contaminated steroid injections, remains the defining case for compounding safety failures. The NECC was operating as a de facto manufacturer while registered as a compounding pharmacy, producing thousands of doses in conditions that inspection later revealed were grossly inadequate: visible contamination, failed environmental monitoring, and lapsed sterility procedures. While peptide compounding has not produced a comparable incident, the NECC case demonstrated that voluntary quality standards and state-level oversight can have fatal gaps.

The NECC disaster led directly to the Drug Quality and Security Act of 2013, which created the 503B outsourcing facility category and gave the FDA explicit authority over these larger-scale compounders. For peptide patients, the practical lesson is that the regulatory framework matters. A 503B facility under FDA inspection operates in a fundamentally different oversight environment than a traditional 503A pharmacy operating under state board of pharmacy jurisdiction alone.

The gray market comparison

Not all injectable peptides come from pharmacies. A substantial parallel market exists where peptides are sold online as "research chemicals" or "for research use only." Van Hout and Hearne (2016) documented user behavior around synthetic growth hormone secretagogue CJC-1295 through netnographic analysis, finding that users frequently purchased from unregulated online sources and self-administered without medical oversight.^[4]

Independent testing of gray-market peptides has found products with no detectable peptide content, incorrect peptide identity, bacterial contamination, and heavy metal residues. These products are not manufactured in clean rooms, are not subject to USP standards, and carry no Certificate of Analysis from a registered facility.

The quality gap between a PCAB-accredited 503B outsourcing facility and a gray-market "research chemical" vendor is enormous. But the gap between a 503B facility and an FDA-approved pharmaceutical manufacturer also exists, particularly in impurity characterization, stability testing depth, and long-term pharmacovigilance.

Analytical methods for detecting peptide quality issues have advanced substantially. Barroso and colleagues (2012) reviewed the analytical challenges in peptide detection and characterization, noting that techniques like LC-MS/MS can identify not just the primary peptide but also degradation products, synthesis-related impurities, and contaminants at very low concentrations.^[5]

The Category 1/Category 2 framework

The FDA classifies bulk drug substances for compounding eligibility:

Category 1: Eligible for compounding. Includes substances with USP monographs, substances on the FDA's positive list, and substances with established use histories. Peptides like semaglutide (for compounding during drug shortage) have been in this category.

Category 2: Under evaluation. The FDA has not determined that these substances meet the criteria for compounding eligibility. Many popular peptides including BPC-157, thymosin alpha-1, and several GH secretagogues were placed in Category 2 in 2023.

In September 2024, a legal settlement required the FDA to submit Category 2 peptides for review by the Pharmacy Compounding Advisory Committee (PCAC) rather than unilaterally banning them. As of early 2026, regulatory discussions continue about reclassifying some Category 2 peptides back to Category 1.

This regulatory uncertainty affects compounding pharmacies directly: a peptide eligible for compounding today may not be tomorrow, and vice versa. State-level regulations add another layer of variability.

What patients cannot verify

Even with all these quality frameworks, patients receiving compounded peptides face an information asymmetry that does not exist with FDA-approved drugs. There is no public adverse event reporting database specific to compounded products. Lot-specific testing results are not routinely shared with patients. Certificate of Analysis documents from API suppliers are not standardized in format or accessibility. And the critical distinction between "this vial passed potency testing" and "this vial is functionally equivalent to the pharmaceutical version" is not visible from the outside.

The most reliable indicator available to patients is pharmacy accreditation status (PCAB or equivalent), 503A versus 503B registration, and willingness to provide testing documentation upon request. Pharmacies that voluntarily exceed minimum requirements, performing stability testing, third-party potency verification, and comprehensive impurity analysis, represent the higher end of the quality spectrum. But these practices are not universal, and identifying which pharmacies follow them requires asking specific questions that most patients do not know to ask.

The Bottom Line

Compounding pharmacies formulate injectable peptides from bulk APIs under USP 797 sterile standards, with required testing for sterility, endotoxin, potency, and purity. Manufacturing process differences can produce measurable quality variations, and even trace impurities can alter peptide biological activity. The quality gap between accredited compounding pharmacies and gray-market sources is vast, but differences between compounded and pharmaceutical-grade peptides also exist in impurity characterization and pharmacovigilance. Regulatory frameworks continue to evolve, with FDA Category 1/2 classifications determining which peptides can legally be compounded.

Frequently Asked Questions

Do compounding pharmacies synthesize peptides?

No. Compounding pharmacies do not perform solid-phase peptide synthesis. They purchase bulk lyophilized peptide API from FDA-registered manufacturers and formulate it into patient-ready injectable preparations under sterile conditions per USP 797 standards. The synthesis occurs at dedicated manufacturing facilities.

What quality testing do compounded peptides undergo?

Compliant pharmacies test for sterility (USP 71), bacterial endotoxin (USP 85 LAL assay), potency (typically HPLC, 90-110% of label), and identity. Purity testing measures degradation products and impurities. However, the depth of testing varies between pharmacies and is generally less comprehensive than FDA-approved drug testing.

What is USP 797 and why does it matter for peptides?

USP General Chapter 797 sets mandatory standards for sterile compounding in the US, covering clean room requirements (ISO Class 5), environmental monitoring, personnel competency testing, beyond-use dating, and preparation procedures. The revised chapter (effective November 2023) raised requirements for all sterile preparations, directly affecting how compounding pharmacies produce injectable peptides.

Are compounded peptides the same quality as pharmaceutical drugs?

Not necessarily. While potency may be equivalent, impurity profiles can differ. Hach et al. (2024) showed that manufacturing process differences produce measurable quality variations in polypeptide preparations. Verbeken et al. (2012) demonstrated that even trace impurity differences can alter biological activity. Pharmaceutical drugs undergo more extensive characterization and have structured pharmacovigilance systems that compounded products lack.

What is the difference between 503A and 503B pharmacies?

Section 503A pharmacies compound patient-specific prescriptions with limited oversight. Section 503B outsourcing facilities can compound without individual prescriptions, in larger batches, but must register with the FDA and comply with current Good Manufacturing Practice (cGMP) requirements. 503B facilities face more rigorous inspection and testing standards.

Are gray-market research peptides safe?

Independent testing has found gray-market peptides sold as "research use only" with no detectable peptide content, wrong peptide identity, bacterial contamination, and heavy metal residues. These products are manufactured outside clean room environments without USP standards, Certificates of Analysis from registered facilities, or any regulatory oversight. The quality gap between regulated compounding and unregulated sources is substantial.